Nothing Special   »   [go: up one dir, main page]

SE0203754D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0203754D0
SE0203754D0 SE0203754A SE0203754A SE0203754D0 SE 0203754 D0 SE0203754 D0 SE 0203754D0 SE 0203754 A SE0203754 A SE 0203754A SE 0203754 A SE0203754 A SE 0203754A SE 0203754 D0 SE0203754 D0 SE 0203754D0
Authority
SE
Sweden
Prior art keywords
alkylnr
alkylc
solvate
cycloalkyl
phenyl
Prior art date
Application number
SE0203754A
Other languages
English (en)
Inventor
Stefan Berg
Sven Hellberg
Peter Soederman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0203754A priority Critical patent/SE0203754D0/sv
Publication of SE0203754D0 publication Critical patent/SE0203754D0/sv
Priority to EP03781204A priority patent/EP1575938B1/en
Priority to MXPA05006243A priority patent/MXPA05006243A/es
Priority to DE60330910T priority patent/DE60330910D1/de
Priority to CNB2003801066631A priority patent/CN100351250C/zh
Priority to AT03781204T priority patent/ATE454382T1/de
Priority to KR1020057011137A priority patent/KR101110457B1/ko
Priority to AU2003287135A priority patent/AU2003287135B2/en
Priority to ES03781204T priority patent/ES2337682T3/es
Priority to PCT/SE2003/001955 priority patent/WO2004055005A1/en
Priority to EP09180635A priority patent/EP2161265A3/en
Priority to US10/539,543 priority patent/US7585853B2/en
Priority to NZ540449A priority patent/NZ540449A/en
Priority to JP2004560223A priority patent/JP4674088B2/ja
Priority to CA2508042A priority patent/CA2508042C/en
Priority to BR0317294-5A priority patent/BR0317294A/pt
Priority to IL169016A priority patent/IL169016A/en
Priority to NO20053460A priority patent/NO331495B1/no
Priority to ZA200504617A priority patent/ZA200504617B/en
Priority to HK06100896.9A priority patent/HK1080856A1/xx
Priority to US12/545,213 priority patent/US20100075989A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SE0203754A 2002-12-17 2002-12-17 New compounds SE0203754D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE0203754A SE0203754D0 (sv) 2002-12-17 2002-12-17 New compounds
BR0317294-5A BR0317294A (pt) 2002-12-17 2003-12-15 Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
ES03781204T ES2337682T3 (es) 2002-12-17 2003-12-15 Compuestos que tienen un efecto inhibidor selectivo de la gsk3.
EP09180635A EP2161265A3 (en) 2002-12-17 2003-12-15 Compounds having selective inhibiting effect at GSK3
DE60330910T DE60330910D1 (de) 2002-12-17 2003-12-15 Verbindungen mit selektiverinhibierender wirkung für gsk3
CNB2003801066631A CN100351250C (zh) 2002-12-17 2003-12-15 对gsk3具有选择性抑制作用的新型化合物
AT03781204T ATE454382T1 (de) 2002-12-17 2003-12-15 Verbindungen mit selektiverinhibierender wirkung für gsk3
KR1020057011137A KR101110457B1 (ko) 2002-12-17 2003-12-15 Ｇｓｋ3에서 선택적 저해 효과를 갖는 신규 화합물
AU2003287135A AU2003287135B2 (en) 2002-12-17 2003-12-15 Novel compounds having selective inhibiting effect at GSK3
EP03781204A EP1575938B1 (en) 2002-12-17 2003-12-15 Compounds having selective inhibiting effect at gsk3
PCT/SE2003/001955 WO2004055005A1 (en) 2002-12-17 2003-12-15 Novel compounds having selective inhibiting effect at gsk3
MXPA05006243A MXPA05006243A (es) 2002-12-17 2003-12-15 Compuestos novedosos que tienen un efecto de inhibicion selectiva en gsk3.
US10/539,543 US7585853B2 (en) 2002-12-17 2003-12-15 Compounds having selective inhibiting effect at GSK3
NZ540449A NZ540449A (en) 2002-12-17 2003-12-15 Novel compounds having selective inhibiting effect at GSK3
JP2004560223A JP4674088B2 (ja) 2002-12-17 2003-12-15 Ｇｓｋ３で選択的な阻害作用を示す新規な化合物
CA2508042A CA2508042C (en) 2002-12-17 2003-12-15 Pyridine/pyrazine-2-carboxamide derivatives and uses thereof
IL169016A IL169016A (en) 2002-12-17 2005-06-06 Phenyl pyrene carboxylic acid compounds have a selective inhibitory effect on gsk3, medicinal preparations containing them, and their use in the preparation of drugs
NO20053460A NO331495B1 (no) 2002-12-17 2005-07-15 Nye forbindelser med selektiv inhiberende effekt ved GSK3
ZA200504617A ZA200504617B (en) 2002-12-17 2006-01-16 Novel compounds having selective inhibiting effect at GSK3
HK06100896.9A HK1080856A1 (en) 2002-12-17 2006-01-19 Compounds having selective inhibiting effect at gsk3
US12/545,213 US20100075989A1 (en) 2002-12-17 2009-08-21 Novel Compounds Having Selective Inhibiting Effect at GSK3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203754A SE0203754D0 (sv) 2002-12-17 2002-12-17 New compounds

Publications (1)

Publication Number Publication Date
SE0203754D0 true SE0203754D0 (sv) 2002-12-17

Family

ID=20289907

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203754A SE0203754D0 (sv) 2002-12-17 2002-12-17 New compounds

Country Status (19)

Country Link
US (2) US7585853B2 (sv)
EP (2) EP1575938B1 (sv)
JP (1) JP4674088B2 (sv)
KR (1) KR101110457B1 (sv)
CN (1) CN100351250C (sv)
AT (1) ATE454382T1 (sv)
AU (1) AU2003287135B2 (sv)
BR (1) BR0317294A (sv)
CA (1) CA2508042C (sv)
DE (1) DE60330910D1 (sv)
ES (1) ES2337682T3 (sv)
HK (1) HK1080856A1 (sv)
IL (1) IL169016A (sv)
MX (1) MXPA05006243A (sv)
NO (1) NO331495B1 (sv)
NZ (1) NZ540449A (sv)
SE (1) SE0203754D0 (sv)
WO (1) WO2004055005A1 (sv)
ZA (1) ZA200504617B (sv)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SI1784396T1 (sl) * 2004-08-26 2011-03-31 Pfizer S pirazolom substituirane aminoheteroarilne spojine kot zaviralci protein-kinaze
DK1786785T3 (da) 2004-08-26 2010-05-31 Pfizer Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
US20100190980A1 (en) * 2007-06-21 2010-07-29 Taisho Pharmaceutical Co., Ltd Pyrazinamide compound
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2138485A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
AU2009313198B2 (en) 2008-11-10 2016-03-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
RU2604066C2 (ru) 2008-12-19 2016-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразина, используемые в качестве ингибиторов киназы atr
AR078984A1 (es) * 2009-11-13 2011-12-14 Astrazeneca Ab Pirazina sustituida con oxazolo (4,5-c) piridina
MX2012008328A (es) * 2010-01-19 2012-08-08 Astrazeneca Ab Derivados de pirazina.
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な化合物
WO2011143399A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP2013526539A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用なピラジン
AU2011253021A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of ATR kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
MX2013000103A (es) 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
JP2014510151A (ja) 2011-04-05 2014-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物
JP6050335B2 (ja) 2011-05-23 2016-12-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ チアゾール誘導体
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
CN108464983A (zh) 2011-09-30 2018-08-31 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014KN00943A (sv) 2011-09-30 2015-08-21 Vertex Pharma
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
WO2013117285A1 (en) 2012-02-09 2013-08-15 Merck Patent Gmbh Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR102213986B1 (ko) 2012-12-07 2021-02-09 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT3077397T (lt) 2013-12-06 2020-01-27 Vertex Pharmaceuticals Inc. 2-amino-6-fluor-n-[5-fluor-piridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamido junginys, naudingas kaip atr kinazės inhibitorius, jo gamyba, skirtingos kietos formos ir jo radioaktyviai žymėti dariniai
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP3152212B9 (en) 2014-06-05 2020-05-27 Vertex Pharmaceuticals Inc. Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
EP3157566B1 (en) 2014-06-17 2019-05-01 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
BR112017010261A2 (pt) * 2014-11-18 2018-02-06 Merck Sharp & Dohme Corp. composto, composição farmacêutica, e, método de tratamento para tratar distúrbios do sistema nervoso central (cns).
MX2018003657A (es) 2015-09-30 2018-04-30 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr).

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA26473A1 (fr) * 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
EE200200453A (et) * 2000-02-16 2003-12-15 Neurogen Corporation Asendatud arüülpürasiinid
AU784827B2 (en) * 2000-03-07 2006-06-29 Sanofi-Aventis Deutschland Gmbh Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
EP1406884A1 (en) * 2001-05-11 2004-04-14 Biovitrum Ab Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
SE0203752D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
JP4674088B2 (ja) 2011-04-20
US20100075989A1 (en) 2010-03-25
NO331495B1 (no) 2012-01-16
EP1575938A1 (en) 2005-09-21
EP2161265A2 (en) 2010-03-10
CN100351250C (zh) 2007-11-28
CA2508042A1 (en) 2004-07-01
WO2004055005A8 (en) 2005-06-30
NZ540449A (en) 2008-02-29
CA2508042C (en) 2012-01-10
JP2006513180A (ja) 2006-04-20
KR101110457B1 (ko) 2012-02-17
ZA200504617B (en) 2006-03-29
HK1080856A1 (en) 2006-05-04
MXPA05006243A (es) 2005-08-19
BR0317294A (pt) 2005-11-08
US7585853B2 (en) 2009-09-08
US20060116362A1 (en) 2006-06-01
NO20053460L (no) 2005-08-12
IL169016A (en) 2013-08-29
EP2161265A3 (en) 2010-06-02
CN1729185A (zh) 2006-02-01
EP1575938B1 (en) 2010-01-06
ES2337682T3 (es) 2010-04-28
DE60330910D1 (de) 2010-02-25
AU2003287135B2 (en) 2007-01-25
KR20050084363A (ko) 2005-08-26
AU2003287135A1 (en) 2004-07-09
ATE454382T1 (de) 2010-01-15
WO2004055005A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
SE0203754D0 (sv) New compounds
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
BG108420A (en) New indole derivatives with 5-ht6 receptor affinity
CY1110904T1 (el) Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun
UY27368A1 (es) Nuevos compuestos
AR032877A1 (es) Inhibidores alquil c(1-6)-4-amino-azepan-3-onicos de proteasas, composiciones farmaceuticas que los comprenden, intermediarios utiles en la preparacion de tales compuestos, procedimiento para la sintesis de dichos inhibidores, y uso de dichos inhibidores en la fabricacion de medicamentos
MXPA04007414A (es) Indoles sustituidos como agonistas alfa-1.
SE0100569D0 (sv) New compounds
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
NO20015172L (no) 1-metyl-erytromycin-derivater
PA8466201A1 (es) Compuestos de indol 2,3-sustituidos como agentes antiinflamatorios y analgesicos
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
SE0102055D0 (sv) New Compounds
SE0102440D0 (sv) New compound
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
TW200505905A (en) New compounds
NZ543068A (en) Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them
SE9900190D0 (sv) New compounds
SE0301371D0 (sv) New Compounds